StockpollyBeta
Get App
Popularity #4,843
ATNM · AMEX · Biotechnology

Actinium Pharmaceuticals (ATNM)

Develops targeted radiotherapies for cancer and transplant conditioning.

$1.19
vs last close+0.02 (+1.71%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000035
Cost of revenue00000000−100
Gross profit000000001035
109121271786767
Research & development869105854545
23433932222
General & administrative23000932222
Other expenses00000000000
Operating income−10−10−12−13−8−17−8−6−6−628
11111111000
Interest income11111111−200
Other non-operating income−1−1−1−1−1−1−1−1000
Income before tax−9−9−11−12−7−16−7−5−6−628
Net income from continuing operations−9−9−11−12−7−16−7−5−6−628
Net income−9−9−11−12−7−16−7−5−6−628
EPS, basic−$0.34−$0.31−$0.38−$0.37−$0.21−$0.51−$0.22−$0.16−$0.19−$0.18$0.89
EPS, diluted−$0.34−$0.31−$0.38−$0.37−$0.21−$0.51−$0.22−$0.16−$0.19−$0.18$0.89
Weighted average shares, basic2828303131313131313131
Weighted average shares, diluted2828303131313131313131
EBITDA−9−8−11−11−6−16−7−5−6−528
Depreciation & amortization00000000000
EBIT−9−9−11−12−7−16−7−5−6−628